Biden is in seriously hot water this week, as two long-standing FDA officials decided to step down from their jobs after a reported ‘disagreement’ with Biden’s White House over the administration of more booster shots. Biden is pushing the booster shots even though there is no evidence that another shot is need among those in the general population. In fact, an entire international group of scientists is stepping down because of Biden’s choice to prioritize politics over science.
The FDA’s direct of the Office of Vaccines and Research/Review, Marion Gruber, as well as the deputy director, a Mr. Phil Krause, are preparing to leave in November and October, They published their views on Monday in the Lancet, along with many experts around the world, saying that the first round of vaccines remains high effective against COVID and prevent severe disease, even against the dominant and highly transmissible delta variant.
The authors went on to say that careful public scrutiny of the constantly-evolving data is necessary to ensure that the decisions about booster shots are being made by science and not politics, and that widespread booster shots should only happen if there is clear evidence that they are needed and appropriate.
These comments come directly after the FDA’s acting commissioner, Janet Woodcock and the CDC’s director, Dr. Rochelle Walensky, advised the White House and Biden that more time is needed for regulators to review data before a booster shot plan is put in place.
As of right now, there is only evidence that a very few people that received Pfizer’s vaccine are in need of a booster shot right now. Just last month, some of the nation’s leading health officials told the U.S. that they were going to be offering booster shots starting sometime in September, per FDA review. It’s no surprise that this advice comes from Dr. Fauci and his friend at the NIH, as well as Dr. Vivek Murthy, the U.S. surgeon general. They claim that over time the protection from the vaccine wanes, especially in high-risk individuals or those who got the vaccine earlier during the rollout.
Krause, Gruber and the other authors begged for caution when coming to conclusion about efficacy for the vaccine, saying that some studies were done with ‘selective reporting’ and shouldn’t be used to make the booster shot decision. They also say that vaccines should instead be targeted and allocated to those who are not vaccinated to reduce the risk of severe illness and the risk of new variants.
Author: Betty Brandhouse